Literature DB >> 18258208

Gene expression profiling of mucolipidosis type IV fibroblasts reveals deregulation of genes with relevant functions in lysosome physiology.

Andrea Bozzato1, Sergio Barlati, Giuseppe Borsani.   

Abstract

Mucolipidosis type IV (MLIV, MIM 252650) is an autosomal recessive lysosomal storage disorder that causes mental and motor retardation as well as visual impairment. The lysosomal storage defect in MLIV is consistent with abnormalities of membrane traffic and organelle dynamics in the late endocytic pathway. MLIV is caused by mutations in the MCOLN1 gene, which codes for mucolipin-1 (MLN1), a member of the large family of transient receptor potential (TRP) cation channels. Although a number of studies have been performed on mucolipin-1, the pathological mechanisms underlying MLIV are not fully understood. To identify genes that characterize pathogenic changes in mucolipidosis type IV, we compared the expression profiles of three MLIV and three normal skin fibroblasts cell lines using oligonucleotide microarrays. Genes that were differentially expressed in patients' cells were identified. 231 genes were up-regulated, and 116 down-regulated. Real-Time RT-PCR performed on selected genes in six independent MLIV fibroblasts cell lines was generally consistent with the microarray findings. This study allowed to evidence the modulation at the transcriptional level of a discrete number of genes relevant in biological processes which are altered in the disease such as endosome/lysosome trafficking, lysosome biogenesis, organelle acidification and lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258208     DOI: 10.1016/j.bbadis.2008.01.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  TRPMLs: in sickness and in health.

Authors:  Rosa Puertollano; Kirill Kiselyov
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-21

Review 2.  TRPML: transporters of metals in lysosomes essential for cell survival?

Authors:  Kirill Kiselyov; Grace A Colletti; Austen Terwilliger; Kathleen Ketchum; Christopher W P Lyons; James Quinn; Shmuel Muallem
Journal:  Cell Calcium       Date:  2011-05-31       Impact factor: 6.817

3.  LAPTMs regulate lysosomal function and interact with mucolipin 1: new clues for understanding mucolipidosis type IV.

Authors:  Silvia Vergarajauregui; Jose A Martina; Rosa Puertollano
Journal:  J Cell Sci       Date:  2011-01-11       Impact factor: 5.285

4.  Gene expression in cell lines from propionic acidemia patients, carrier parents, and controls.

Authors:  Kimberly A Chapman; William S Bush; Zhe Zhang
Journal:  Mol Genet Metab       Date:  2015-05-08       Impact factor: 4.797

Review 5.  The role of TRPMLs in endolysosomal trafficking and function.

Authors:  Kartik Venkatachalam; Ching-On Wong; Michael X Zhu
Journal:  Cell Calcium       Date:  2014-10-28       Impact factor: 6.817

6.  Lysosomal TRPML1 Channel: Implications in Cardiovascular and Kidney Diseases.

Authors:  Guangbi Li; Pin-Lan Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  ESCRT-Dependent Cell Death in a Caenorhabditis elegans Model of the Lysosomal Storage Disorder Mucolipidosis Type IV.

Authors:  Julie M Huynh; Hope Dang; Isabel A Munoz-Tucker; Marvin O'Ketch; Ian T Liu; Savannah Perno; Natasha Bhuyan; Allison Crain; Ivan Borbon; Hanna Fares
Journal:  Genetics       Date:  2015-11-23       Impact factor: 4.562

8.  The diagnosis of inherited metabolic diseases by microarray gene expression profiling.

Authors:  Monica Arenas Hernandez; Reiner Schulz; Tracy Chaplin; Bryan D Young; David Perrett; Michael P Champion; Jan-Willem Taanman; Anthony Fensom; Anthony M Marinaki
Journal:  Orphanet J Rare Dis       Date:  2010-12-01       Impact factor: 4.123

9.  Proteomics analysis of a human brain sample from a mucolipidosis type IV patient reveals pathophysiological pathways.

Authors:  Ayelet Vardi; Amir Pri-Or; Noa Wigoda; Yulia Grishchuk; Anthony H Futerman
Journal:  Orphanet J Rare Dis       Date:  2021-01-21       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.